uniQure (QURE) Stock: Falls 3% Despite FDA Priority Review for Huntington’s Disease Gene Therapy
TLDR QURE stock falls 2.98% to $24.09 despite FDA Priority Review for AMT-130. FDA sets May 1, 2027, as the…
Market coverage 1 stories
TLDR QURE stock falls 2.98% to $24.09 despite FDA Priority Review for AMT-130. FDA sets May 1, 2027, as the…